ArticleBMC pulmonary medicine2026
Diagnostic value of EBUS-TBNA for intrathoracic tuberculous lymphadenitis: a retrospective cohort analysis stratified by anti-tuberculosis treatment duration.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is widely adopted to diagnose intrathoracic lymphadenopathy, including tuberculous lymphadenitis (TBLA). However, the influence of anti-tuberculosis (anti-TB) treatment duration on its diagnostic yield remains unclear.
methodsIn this retrospective cohort study, 78patients with suspected intrathoracic TBLA who underwent EBUS-TBNA between June 2017 and January 2024 were included. Patients were categorized into four groups by prior anti-TB treatment duration. Composite diagnostic criteria incorporating histopathology, microbiology, and treatment response were used as the reference standard. Diagnostic performance across lymph node stations and modalities was analyzed. Safety outcomes were also evaluated.
resultsThe overall diagnostic sensitivity of EBUS-TBNA based on composite criteria was 96.2%. Stratified analysis showed no statistically significant difference in diagnostic positivity among untreated (95.9%), 1-30 days (83.3%), 31-180 days (100%), and > 180 days (100%) groups (P = 0.42). Diagnostic yield was consistent across mediastinal, hilar, and combined lymph node stations (P = 0.289). Among diagnostic modalities, TB-DNA, histopathology TB-SPOT and sputum Xpert demonstrated high positivity rates. No major complications occurred; minor self-limited bleeding was observed in 15.4% of patients.
conclusionEBUS-TBNA is a safe and effective diagnostic tool for intrathoracic TBLA, with consistent performance in both treatment-naïve and pretreated patients, regardless of anti-TB therapy duration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.